WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584169
CAS#: 127245-22-1
Description: Biofor 389 is a potent, orally active, antiarthritic and analgesic agent with low ulcerogenic potential.
Hodoodo Cat#: H584169
Name: Biofor 389
CAS#: 127245-22-1
Chemical Formula: C20H29NO3
Exact Mass: 331.21
Molecular Weight: 331.456
Elemental Analysis: C, 72.47; H, 8.82; N, 4.23; O, 14.48
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BF 389
IUPAC/Chemical Name: 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-
InChi Key: BWRYNNCGEDOTRW-GXDHUFHOSA-N
InChi Code: InChI=1S/C20H29NO3/c1-19(2,3)15-11-13(12-16(17(15)22)20(4,5)6)10-14-8-9-24-21(7)18(14)23/h10-12,22H,8-9H2,1-7H3/b14-10+
SMILES Code: O=C1N(C)OCC/C1=C\C2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 331.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Veerhuis R, Hoozemans JJ, Janssen I, Boshuizen RS, Langeveld JP, Eikelenboom P. Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2. Brain Res. 2002 Jan 25;925(2):195-203. PubMed PMID: 11792368.
2: Blom MA, van Twillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R, Eikelenboom P. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res. 1997 Nov 28;777(1-2):210-8. PubMed PMID: 9449430.
3: Wong S, Lee SJ, Frierson MR 3rd, Proch J, Miskowski TA, Rigby BS, Schmolka SJ, Naismith RW, Kreutzer DC, Lindquist R. Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. PubMed PMID: 1456184.
4: Bendele AM, Ruterbories KJ, Spaethe SM, Benslay DN, Lindstrom TD, Lee SJ, Naismith RW. Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389. J Pharmacol Exp Ther. 1992 Mar;260(3):1194-8. PubMed PMID: 1545387.
5: Bendele AM, Benslay DN, Hom JT, Spaethe SM, Ruterbories KJ, Lindstrom TD, Lee SJ, Naismith RW. Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. J Pharmacol Exp Ther. 1992 Jan;260(1):300-5. PubMed PMID: 1309875.
